Citius Oncology (NASDAQ: CTOR) announced it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH).
According to Citius, the agreement is designed to help provide access to LYMPHIR, an innovative immunotherapy, which is FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL)—in support of its anticipated U.S. commercial launch. Under the agreement, Cardinal will serve as an authorized distributor of record for Citius providing specialty pharmaceutical distribution services.
Leonard Mazur, chairman and CEO of Citius Oncology and Citius Pharmaceuticals, commented, “This agreement marks a key step forward in our launch readiness efforts. Cardinal Health’s proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network.”
